Galectin Therapeutics (GALT) Earnings Date, Estimates & Call Transcripts → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free GALT Stock Alerts $2.64 -0.07 (-2.58%) (As of 03:08 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateAug. 12EstimatedActual EPS (May. 15) -$0.19 Missed By -$0.03 Consensus EPS (May. 15) -$0.16 Get Galectin Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for GALT and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueGALT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.GALT Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Oasis GoldExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! Galectin Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.16)($0.16)($0.16)Q2 20241($0.16)($0.16)($0.16)Q3 20241($0.17)($0.17)($0.17)Q4 20241($0.17)($0.17)($0.17)FY 20244($0.66)($0.66)($0.66)GALT Earnings Date and InformationGalectin Therapeutics last released its quarterly earnings data on May 15th, 2024. The reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.03. Galectin Therapeutics has generated ($0.74) earnings per share over the last year (($0.74) diluted earnings per share). Earnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.66) to ($1.59) per share. Galectin Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off prior year's report dates.Read More Galectin Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/12/2024(Estimated)------- 5/15/2024Q1 2024($0.16)($0.19)($0.03)($0.19)--3/29/2024Q4 2023-($0.16)($0.16)($0.16)--11/13/2023Q3 2023($0.16)($0.24)($0.08)($0.24)--8/14/2023Q2 2023($0.21)($0.15)+$0.06($0.15)--5/15/2023Q1 2023($0.21)($0.19)+$0.02($0.19)--3/30/2023Q4 2022($0.17)($0.18)($0.01)($0.18)-- Get the Latest News and Ratings for GALT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/14/2022Q3 2022($0.20)($0.14)+$0.06($0.14)--8/15/2022Q2 2022($0.19)($0.16)+$0.03($0.16)--5/16/2022Q1 2022($0.10)($0.17)($0.07)($0.17)--3/31/2022Q4 2021-($0.13)($0.13)($0.14)--11/15/2021Q3 2021($0.18)($0.14)+$0.04($0.14)--8/16/2021Q2 2021($0.18)($0.15)+$0.03($0.15)--5/16/2021Q1 2021($0.17)($0.11)+$0.06($0.11)--3/30/2021Q4($0.16)($0.14)+$0.02($0.14)--11/9/2020Q3 2020($0.14)($0.10)+$0.04($0.10)--8/10/2020Q2 2020($0.07)($0.11)($0.04)($0.11)--5/11/2020Q1 2020($0.08)($0.06)+$0.02($0.06)--3/16/2020Q4 2019($0.06)($0.12)($0.06)($0.12)--11/12/2019Q3 2019($0.08)($0.0498)+$0.0302($0.05)--8/9/2019Q2 2019($0.10)($0.06)+$0.04($0.06)-- Galectin Therapeutics Earnings - Frequently Asked Questions When is Galectin Therapeutics's earnings date? Galectin Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off last year's report dates. Learn more on GALT's earnings history. Did Galectin Therapeutics beat their earnings estimates last quarter? In the previous quarter, Galectin Therapeutics (NASDAQ:GALT) missed the analysts' consensus estimate of ($0.16) by $0.03 with a reported earnings per share (EPS) of ($0.19). Learn more on analysts' earnings estimate vs. GALT's actual earnings. How much profit does Galectin Therapeutics generate each year? Galectin Therapeutics (NASDAQ:GALT) has a recorded net income of -$41.07 million. GALT has generated -$0.74 earnings per share over the last four quarters. What is Galectin Therapeutics's EPS forecast for next year? Galectin Therapeutics's earnings are expected to decrease from ($0.66) per share to ($1.59) per share in the next year. More Earnings Resources from MarketBeat Related Companies: LUMO Earnings ZYME Earnings HROW Earnings ANAB Earnings SAGE Earnings GHRS Earnings AVBP Earnings PHAT Earnings LYEL Earnings SLN Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: CrowdStrike's Earnings: Consolidation and AI-Driven Growth The Most Upgraded Stocks After the Q1 Earnings Season ZIM Shipping Stock Forecast, Earnings Triggers a BuyAmerican Superconductor's Earnings Surge, Future Growth ExpectedHormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry ShiftsAbercrombie & Fitch First Quarter Earnings Surge to New Heights This page (NASDAQ:GALT) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredNVDA to close the AI “wealth window’ June 25?On Tuesday, June 25, in front of executives from nearly every major tech company in existence, key leaders at ...Paradigm Direct | SponsoredThe Greatest LEGAL Transfer of Wealth in History is UnderwayWhat's the #1 Stock to Build Generational Wealth RIGHT NOW? One Wall Street millionaire will give you a sur...Stansberry Research | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.